Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Condition(s):Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and CholangiocarcinomaLast Updated:December 19, 2023Completed